Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Accured Expenses (2020 - 2025)

Gain Therapeutics has reported Change in Accured Expenses over the past 6 years, most recently at -$785258.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$785258.0 for Q4 2025, down 1252.26% from a year ago — trailing twelve months through Dec 2025 was -$468606.0 (down 270.47% YoY), and the annual figure for FY2025 was -$468606.0, down 270.47%.
  • Change in Accured Expenses for Q4 2025 was -$785258.0 at Gain Therapeutics, up from -$949139.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for GANX hit a ceiling of $1.7 million in Q1 2022 and a floor of -$1.9 million in Q3 2024.
  • Median Change in Accured Expenses over the past 5 years was -$21322.0 (2021), compared with a mean of $59456.4.
  • Biggest five-year swings in Change in Accured Expenses: soared 50338.17% in 2022 and later tumbled 3920.98% in 2024.
  • Gain Therapeutics' Change in Accured Expenses stood at -$589191.0 in 2021, then crashed by 39.6% to -$822482.0 in 2022, then soared by 60.2% to -$327309.0 in 2023, then surged by 82.26% to -$58070.0 in 2024, then plummeted by 1252.26% to -$785258.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$785258.0 (Q4 2025), -$949139.0 (Q3 2025), and $151651.0 (Q2 2025) per Business Quant data.